Stockreport

Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab [Yahoo! Finance]

Jasper Therapeutics, Inc. - Class A  (JSPR) 
PDF UBS initiated coverage of Jasper Therapeutics on March 23, 2026, with a Neutral rating and a $1.50 price target, arguing that competition in the space could limit upsid [Read more]